08:42 AM EDT, 05/05/2025 (MT Newswires) -- Perimeter Medical Imaging AI ( PYNKF ) on Monday reported results from the trial evaluating the use of its latest B-series optical coherence tomography (OCT) technology for intraoperative margin assessment during breast-conserving surgeries (BCS).

The trial met its primary endpoint with statistically significant reduction in patients with residual cancer during surgery compared with standard-of-care alone, the company said.

Of the 206 patients evaluated, 56 residual diseased margins in 35 of the 206 patients remained after intraoperative Standard of Care (SOC) alone. Perimeter's OCT resulted in the correct detection of residual disease in 14 out of 35 (40%) additional patients.

"We believe Perimeter B-Series will empower surgeons to more effectively identify and address residual cancer at the margin - removing less healthy tissue, reducing re-operations, and sparing breast cancer patients the anxiety of waiting days for post-op pathology results. The goal of interoperative margin assessment with OCT-AI is a single, successful surgery so these patients can return to their lives and loved ones sooner," said Perimeter's Chief Executive Officer, Adrian Mendes.

The trial results were presented this past Saturday during the scientific session of the 26th Annual Meeting of the American Society of Breast Surgeons (ASBrS).